ArticleOncotarget2018

Combination of AKT inhibitor ARQ 092 and sorafenib potentiates inhibition of tumor progression in cirrhotic rat model of hepatocellular carcinoma.

Zuzana Macek Jilkova et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.